Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Albanell

Showing results (11-20 of 93) with videos related to

Pageof 10
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 28, 2007
mTOR signalling in human cancerJ Albanell, A Dalmases, A Rovira, et al.
Critical Reviews in Oncology/Hematology|July 22, 2008
Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agentsJ Bellmunt, S Albiol, C Suárez, et al.
Seminars in Oncology|November 14, 2001
Mechanism of action of trastuzumab and scientific updateJ Baselga, J Albanell, M A Molina, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2001
A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancerJ Bellmunt, R de Wit, J Albanell, et al.
Medicina Clinica|September 21, 1991
[Antineoplastic chemotherapy in digestive tumors]J Bellmunt, J Albanell, O S Gallego, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 3, 2007
Pharmacodynamics: biological activity of targeted therapies in clinical trialsF Rojo, A Dalmases, J M Corominas, et al.
Medicina Clinica|November 21, 1992
[Prognostic factors in breast cancer with negative lymph nodes]J Albanell Mestres, J Bellmunt Molins, L A Solé Calvo
Journal of the National Cancer Institute|March 5, 1997
Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor supportA Ribas, J Albanell, J Bellmunt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2015
Potential clinical relevant drug-drug interactions: comparison between different compendia, do we have a validated method?D Conde-Estévez, D Echeverría-Esnal, I Tusquets, et al.
Cancer Research|July 14, 1998
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenograftsJ Baselga, L Norton, J Albanell, et al.
Pageof 10

Showing results (11-20 of 93) with videos related to

Sort By:
Pageof 10
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 28, 2007
mTOR signalling in human cancerJ Albanell, A Dalmases, A Rovira, et al.
Critical Reviews in Oncology/Hematology|July 22, 2008
Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agentsJ Bellmunt, S Albiol, C Suárez, et al.
Seminars in Oncology|November 14, 2001
Mechanism of action of trastuzumab and scientific updateJ Baselga, J Albanell, M A Molina, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2001
A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancerJ Bellmunt, R de Wit, J Albanell, et al.
Medicina Clinica|September 21, 1991
[Antineoplastic chemotherapy in digestive tumors]J Bellmunt, J Albanell, O S Gallego, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 3, 2007
Pharmacodynamics: biological activity of targeted therapies in clinical trialsF Rojo, A Dalmases, J M Corominas, et al.
Medicina Clinica|November 21, 1992
[Prognostic factors in breast cancer with negative lymph nodes]J Albanell Mestres, J Bellmunt Molins, L A Solé Calvo
Journal of the National Cancer Institute|March 5, 1997
Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor supportA Ribas, J Albanell, J Bellmunt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2015
Potential clinical relevant drug-drug interactions: comparison between different compendia, do we have a validated method?D Conde-Estévez, D Echeverría-Esnal, I Tusquets, et al.
Cancer Research|July 14, 1998
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenograftsJ Baselga, L Norton, J Albanell, et al.
Pageof 10